Development of narsoplimab in the kidney disease has been called off, making a forthcoming regulatory decision in a different use all the more important.

A Phase III hit is always nice but a lot more information will be required to judge iptacopan’s market potential.

Pink Sheet analysis finds big jump in the share of novel approvals that received PDUFA extensions, largely driven by clinical and safety data submissions.

KIMCo CEO Kevin Kyunghwa Huh talks about the consortium's efforts to become a platform of collaboration for Korean pharmas, including plans for the latest joint investment project as well as how the domestic industry is evolving in terms of globalization and open innovation.